Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Breast Cancer Research

Table 3 Logistic regression analysis between stratified clinical parameter (response to treatment) and stratified biomarkers, showing the p value, odds ratio and the 95% confidence interval for this odds ratio

Categorical variable to analyse	Variable	p value	Odds ratio	95% CI for OR		Type of analysis	Type of variable
Categorical variable to analyse	Variable	p value	Odds ratio	Lower	Upper	Type of analysis	Type of variable
Response (RECIST 3 categories) vs
Responding	CTC threshold	Reference category				Univariate	Stratified biomarker
Stable disease		0.256	2.484	0.516	11.955
Progressive disease		0.007	7.966	1.783	35.587
Responding	cfDNA threshold	*Cannot be quantified				Univariate	Stratified biomarker
Stable disease
Progressive disease
Responding	CA15-3 threshold	Reference category				Univariate	Stratified biomarker
Stable disease		0.007	0.265	0.101	0.695
Progressive disease		0.977	1.014	0.382	2.694
Responding	AP threshold	Reference category				Univariate	Stratified biomarker
Stable disease		0.635	1.485	0.29	7.597
Progressive disease		0.01	7.233	1.616	32.373

*Cannot be quantified as all patients in the group responding to treatment have low levels of cfDNA. No patients with high levels of cfDNA responding to treatment

ISSN: 1465-542X